Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company focused on the domestic pharmaceutical and life-sciences sector, targeting businesses aligned with U.S.-based drug development and manufacturing. The company filed a Form 10-Q with the SEC on May 14, 2026, accession number 0001213900-26-056798, indicating it remains an active reporting entity still in the search phase of its SPAC lifecycle. DMAA's sector focus places it within the broader healthcare and pharmaceutical industry at a time of sustained policy attention on domestic drug supply chains. Visit SpacDesk and sign up for full data, filings, and analytics on DMAA and hundreds of other active SPACs.